In France, more than a million people are affected by a neurodegenerative disease. There are around 200,000 patients in France, and 25,000 new cases occur each year. This chronic neurodegenerative pathology is characterized by the progressive disappearance of certain neurons in the brain. While currently the therapies improve symptoms, they are not effective in the advanced stages of the disease. They also do not cure the disease or treat it in its entirety.
It is believed that the alpha-synuclein protein, present in the human brain, forms toxic clumps in these cells, which causes the disease. Currently, prescribed drugs aim to compensate for theinsufficient dopamine production. In Israel, researchers from Ben-Gurion University in the Negev discovered that the BMP5 / 7 protein offered promising therapies that could slow or stop the progression of Parkinson’s disease. The results were published in the journal of Clinical Neurology Brain.
Slow down the disease
Dr Claude Brodski, head of the BGU’s Molecular Neuroscience Laboratory, found that BMP5 / 7 signaling in neurons was dramatically reduced in dopamine-producing brain cells, which could contribute to the advancement of Parkinson disease. “Indeed, we have found that BMP5 / 7 treatment can, in a mouse model of Parkinson’s disease, effectively prevent movement disorders caused by alpha-synuclein build-up and reverse the loss of dopamine “, summarizes the scientist. Before adding: “These results are very promising, because they suggest that BMP5 / 7 may slow or stop the progression of Parkinson’s disease. Currently, we are concentrating all our efforts on bringing our discovery closer to clinical application “.
For his part, Dr Galit Mazooz Perlmuter, senior vice-president of business development, bio-pharma at BGN Technologies recalls that there is currently a great need for new therapies to treat Parkinson’s disease. “Dr. Brodski’s findings, although still in their infancy, offer a drug target. We are now seeking an industrial partner for the development of this patent pending invention.”